Matches in Nanopublications for { ?s ?p "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP380876.RAZahv3blsdoTp-rnnsSZskG0Zm0SbUGzSBu-L-2PfdJ4130_assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380876.RAZahv3blsdoTp-rnnsSZskG0Zm0SbUGzSBu-L-2PfdJ4130_provenance.
- NP380801.RA7el2v-Mt2ACK5DZQDYF1c1e2wURoEkNPcUkgLrT3exs130_assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380801.RA7el2v-Mt2ACK5DZQDYF1c1e2wURoEkNPcUkgLrT3exs130_provenance.
- NP495355.RANXXIu1oX3oi-h6tZWnFz4oUtAWjUVzNQ-Xw38UBVmCg130_assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP495355.RANXXIu1oX3oi-h6tZWnFz4oUtAWjUVzNQ-Xw38UBVmCg130_provenance.
- NP495352.RA4BD26lQTNJRBelHMmN9mzpcm_BkDpFPa6o_i55_pvTo130_assertion description "[HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP495352.RA4BD26lQTNJRBelHMmN9mzpcm_BkDpFPa6o_i55_pvTo130_provenance.